[
  {
    "ts": null,
    "headline": "Abbott Laboratories (NYSE:ABT) Expands Diabetes Care with FreeStyle Libre 3 Plus Launch in Canada",
    "summary": "Abbott Laboratories (NYSE:ABT) recently introduced the FreeStyle Libre 3 Plus in Canada, marking an advancement in diabetes management technology with its small, sensor-based glucose monitoring system. This development, alongside other approvals and partnerships like the i-STAT TBI test and mitral valve replacement system, may have bolstered investor confidence contributing to the company's quarterly share price growth of almost 5%. However, against a backdrop of generally rising market...",
    "url": "https://finnhub.io/api/news?id=9b9c7cf0bc5cf187ff25d3b8fd32f2bfd0149d32b8b7b9c10155f64e7dab3b80",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752082129,
      "headline": "Abbott Laboratories (NYSE:ABT) Expands Diabetes Care with FreeStyle Libre 3 Plus Launch in Canada",
      "id": 135839301,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) recently introduced the FreeStyle Libre 3 Plus in Canada, marking an advancement in diabetes management technology with its small, sensor-based glucose monitoring system. This development, alongside other approvals and partnerships like the i-STAT TBI test and mitral valve replacement system, may have bolstered investor confidence contributing to the company's quarterly share price growth of almost 5%. However, against a backdrop of generally rising market...",
      "url": "https://finnhub.io/api/news?id=9b9c7cf0bc5cf187ff25d3b8fd32f2bfd0149d32b8b7b9c10155f64e7dab3b80"
    }
  },
  {
    "ts": null,
    "headline": "Oppenheimer Reiterates ‘Outperform’ Rating on Abbott Laboratories (ABT)",
    "summary": "Abbott Laboratories (NYSE:ABT) is one of the top 10 defensive stocks to consider in a volatile market. On July 3, analysts at Oppenheimer reiterated an ‘Outperform’ rating on the stock and a $14 price target. The bullish stance follows the Centers for Medicare & Medicaid Services (CMS) final decision on transcatheter edge-to-edge repair for the […]",
    "url": "https://finnhub.io/api/news?id=f32b9f5ef9c85188e2aa67a2d8a9da91b4ce26a02086ad4ae0f725c15fe69219",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752066568,
      "headline": "Oppenheimer Reiterates ‘Outperform’ Rating on Abbott Laboratories (ABT)",
      "id": 135835800,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) is one of the top 10 defensive stocks to consider in a volatile market. On July 3, analysts at Oppenheimer reiterated an ‘Outperform’ rating on the stock and a $14 price target. The bullish stance follows the Centers for Medicare & Medicaid Services (CMS) final decision on transcatheter edge-to-edge repair for the […]",
      "url": "https://finnhub.io/api/news?id=f32b9f5ef9c85188e2aa67a2d8a9da91b4ce26a02086ad4ae0f725c15fe69219"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "url": "https://finnhub.io/api/news?id=ef70357988844ca1cf619142109c478d3b3f1d0e05cf9979561bcaf3fdf97108",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752066010,
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "id": 135835801,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
      "url": "https://finnhub.io/api/news?id=ef70357988844ca1cf619142109c478d3b3f1d0e05cf9979561bcaf3fdf97108"
    }
  },
  {
    "ts": null,
    "headline": "Alcon Stock Gains Following UNITY VCS' Approval in Canada",
    "summary": "ALC's UNITY VCS gets Canada's approval, advancing surgical precision with faster, more efficient technology.",
    "url": "https://finnhub.io/api/news?id=e512dee5fd26a3659515bdb5987d777029d5c2fcd8e59019796cdfdde837c333",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752064140,
      "headline": "Alcon Stock Gains Following UNITY VCS' Approval in Canada",
      "id": 135834628,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "ALC's UNITY VCS gets Canada's approval, advancing surgical precision with faster, more efficient technology.",
      "url": "https://finnhub.io/api/news?id=e512dee5fd26a3659515bdb5987d777029d5c2fcd8e59019796cdfdde837c333"
    }
  },
  {
    "ts": null,
    "headline": "Biomarkers Market Research Report 2025-2030 | Assay Kit Demand Surges as Advancements in Omics Technologies Elevate Biomarker Discovery and Diagnostic Precision",
    "summary": "The biomarkers market is poised to grow from USD 62.39 billion in 2025 to USD 104.15 billion by 2030, with a CAGR of 10.8%. This growth is driven by the advantages of assay kits and advancements in genomics, proteomics, and next-generation sequencing, leading to novel biomarker development. Predictive biomarkers are dominant in efficacy biomarkers due to their role in guiding treatment decisions, particularly in oncology and autoimmune diseases. The immunoassays segment led the market in 2024, s",
    "url": "https://finnhub.io/api/news?id=560a41be83c1fb9474666d64f69e3619b1bb63a8f76754618bd42c46a8f77ea3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752050580,
      "headline": "Biomarkers Market Research Report 2025-2030 | Assay Kit Demand Surges as Advancements in Omics Technologies Elevate Biomarker Discovery and Diagnostic Precision",
      "id": 135832062,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The biomarkers market is poised to grow from USD 62.39 billion in 2025 to USD 104.15 billion by 2030, with a CAGR of 10.8%. This growth is driven by the advantages of assay kits and advancements in genomics, proteomics, and next-generation sequencing, leading to novel biomarker development. Predictive biomarkers are dominant in efficacy biomarkers due to their role in guiding treatment decisions, particularly in oncology and autoimmune diseases. The immunoassays segment led the market in 2024, s",
      "url": "https://finnhub.io/api/news?id=560a41be83c1fb9474666d64f69e3619b1bb63a8f76754618bd42c46a8f77ea3"
    }
  },
  {
    "ts": null,
    "headline": "DexCom Is Doubling Down on Its ‘Mistake.’ Why It’s Time to Buy the Stock.",
    "summary": "DexCom’s decision to pursue the Type 2 diabetes market wasn’t faulty. It was management’s execution of its strategy that caused the problem.",
    "url": "https://finnhub.io/api/news?id=30cb32a125d1f05543816093c8d6a2a7b95ffdbc271c378e4cdeaf46a6b5d88e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752039000,
      "headline": "DexCom Is Doubling Down on Its ‘Mistake.’ Why It’s Time to Buy the Stock.",
      "id": 135829816,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "DexCom’s decision to pursue the Type 2 diabetes market wasn’t faulty. It was management’s execution of its strategy that caused the problem.",
      "url": "https://finnhub.io/api/news?id=30cb32a125d1f05543816093c8d6a2a7b95ffdbc271c378e4cdeaf46a6b5d88e"
    }
  }
]